BRPI0508861A - agonistas do receptor y2/y4 seletivo para intervenções terapêuticas - Google Patents

agonistas do receptor y2/y4 seletivo para intervenções terapêuticas

Info

Publication number
BRPI0508861A
BRPI0508861A BRPI0508861-5A BRPI0508861A BRPI0508861A BR PI0508861 A BRPI0508861 A BR PI0508861A BR PI0508861 A BRPI0508861 A BR PI0508861A BR PI0508861 A BRPI0508861 A BR PI0508861A
Authority
BR
Brazil
Prior art keywords
amino acid
acid sequence
receptor
terminal
receptor recognition
Prior art date
Application number
BRPI0508861-5A
Other languages
English (en)
Inventor
Thue Schwartz
Original Assignee
7Tm Pharmas As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0503111A external-priority patent/GB0503111D0/en
Application filed by 7Tm Pharmas As filed Critical 7Tm Pharmas As
Publication of BRPI0508861A publication Critical patent/BRPI0508861A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)

Abstract

AGONISTAS DO RECEPTOR Y2/Y4 SELETIVO PARA INTERVENçõES TERAPêUTICAS. Agonistas do receptor Y, os quais são seletivos para os receptores Y2 e Y4 sobre o receptor Y1 são úteis para o tratamento de, por exemplo, obesidade, são (a) peptídeos PP-dobrados ou imitadores de peptídeos PP-dobrados os quais têm (i) uma seqüência de aminoácidos de reconhecimento do receptor Y C-terminal representada por -X-Thr-Arg-X¬ 3¬ -Arg-Tyr-C(=O)NR¬ 1¬ R¬ 2¬ , em que R¬ 1¬ e R¬ 2¬ são, independentemente, hidrogênio ou alquil C~ 1~ -C~ 6~ , X é Vall, lle, Leu ou Ala, e X¬ 3¬ é Gin ou Asn, ou um variante conservativamente substituído seu no qual Thr é substituído por His ou Asn e/ou Tyr é substituído por Trp ou Phe; e/ou Arg é substituído do Lys, e (ii) uma seqüência de aminoácidos de reconhecimento do receptor Y N-terminal representada por H~ 2~ N-X¬ 1¬ -Pro-X¬ 2¬ -(Glu ou Asp)- em que X¬ 1¬ não está presente ou é um resíduo de aminoácidos, e X¬ 2¬ é Leu ou Ser ou substituições conservativas de Leu ou Ser, ou (b) o referido compreende uma seqüência de aminoácidos de reconhecimento do receptor Y C-terminal conforme definido em (i) acima, a referida seqüência de reconhecimento do receptor sendo fundida a um domínio de seqüência de aminoácidos antififílica compreendendo pelo menos uma volta alfa-helicóide adjacente ao N-terminal da referida seqüência hexapeptídica, a referida volta sendo confinada Em uma configuração helicóide por uma ligação intramolecular covalente, e opcionalmente uma seqüência N-terminal a qual começa com uma seqüência de aminoácidos de reconhecimento do receptor Y conforme definido em (ii) acima.
BRPI0508861-5A 2004-03-17 2005-03-17 agonistas do receptor y2/y4 seletivo para intervenções terapêuticas BRPI0508861A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200400436 2004-03-17
US55893204P 2004-04-01 2004-04-01
US58596404P 2004-07-06 2004-07-06
GB0503111A GB0503111D0 (en) 2005-02-14 2005-02-14 Receptor agonists and their use
PCT/EP2005/002982 WO2005089790A2 (en) 2004-03-17 2005-03-17 Y2/y4 selective receptor agonists for therapeutic interventions

Publications (1)

Publication Number Publication Date
BRPI0508861A true BRPI0508861A (pt) 2007-08-28

Family

ID=49582878

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508861-5A BRPI0508861A (pt) 2004-03-17 2005-03-17 agonistas do receptor y2/y4 seletivo para intervenções terapêuticas

Country Status (11)

Country Link
US (1) US20080261871A1 (pt)
EP (1) EP1786458A2 (pt)
JP (1) JP2007531714A (pt)
AU (1) AU2005224027B2 (pt)
BR (1) BRPI0508861A (pt)
CA (1) CA2560166A1 (pt)
EA (1) EA011861B1 (pt)
GB (1) GB2427550B (pt)
IL (1) IL177682A0 (pt)
MX (1) MXPA06010346A (pt)
WO (1) WO2005089790A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1953763A (zh) * 2004-03-17 2007-04-25 7Tm制药联合股份有限公司 用于治疗性干预的y4选择性受体激动剂
CA2623094A1 (en) * 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
AU2005337116A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
GB0708226D0 (en) * 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
EP2322620A3 (en) 2007-07-09 2011-08-31 Imperial Innovations Ltd. Analogs of human pancreatic polypeptide and their effects on feeding behaviour
EP2342222B1 (en) * 2008-09-22 2018-03-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2012509902A (ja) * 2008-11-24 2012-04-26 エルロン・セラピューティクス・インコーポレイテッド 改善された特性を有するペプチド模倣大環状分子
GB201001333D0 (en) 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
RS57727B1 (sr) 2012-03-22 2018-12-31 Novo Nordisk As Kompozicije glp-1 peptida i njihovo dobijanje
CN105764919B (zh) 2013-11-15 2021-04-27 诺和诺德股份有限公司 在位置35具有β-高精氨酸置换的hPYY(1-36)
WO2015071355A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
EP3307768A1 (en) 2015-06-12 2018-04-18 Novo Nordisk A/S Selective pyy compounds and uses thereof
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
GB202213305D0 (en) * 2022-09-12 2022-10-26 Univ Ulster Compositions for use in the treatment of diabetes or obesity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960701653A (ko) * 1993-03-29 1996-03-28 발라수브라마니암 엠비카이파칸 펩타이드 yy의 유사체 및 그의 용도
DE19605175A1 (de) * 1996-02-13 1997-08-14 Sourovoi Andrej Dr Lipidverbindungen und deren Verwendung
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
JP2004515533A (ja) * 2000-12-14 2004-05-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 代謝障害を治療するためのペプチドｙｙおよびペプチドｙｙアゴニスト
US6588708B2 (en) * 2001-01-29 2003-07-08 The Boeing Company Spacecraft methods and structures for acquiring and determining power-safe attitudes
EP1549336B1 (en) 2002-06-14 2011-01-05 Amylin Pharmaceuticals, Inc. Prevention and/or treatment of ulcerative colitis using pyy or pyy[3-36]
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
CA2545408A1 (en) * 2003-11-25 2005-06-16 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
JP2007529463A (ja) * 2004-03-17 2007-10-25 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ４選択性レセプターアゴニスト
CN1953763A (zh) * 2004-03-17 2007-04-25 7Tm制药联合股份有限公司 用于治疗性干预的y4选择性受体激动剂
AU2005337116A1 (en) * 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
CA2623094A1 (en) * 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions

Also Published As

Publication number Publication date
IL177682A0 (en) 2006-12-31
AU2005224027B2 (en) 2011-05-26
AU2005224027A1 (en) 2005-09-29
EP1786458A2 (en) 2007-05-23
GB0618812D0 (en) 2006-11-08
US20080261871A1 (en) 2008-10-23
MXPA06010346A (es) 2007-04-23
EA200601722A1 (ru) 2007-04-27
EA011861B1 (ru) 2009-06-30
JP2007531714A (ja) 2007-11-08
GB2427550B (en) 2007-05-30
GB2427550A (en) 2007-01-03
CA2560166A1 (en) 2005-09-29
WO2005089790A3 (en) 2005-12-01
WO2005089790A2 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
BRPI0508861A (pt) agonistas do receptor y2/y4 seletivo para intervenções terapêuticas
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
MXPA06010347A (es) Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
PE20171325A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
HRP20201353T1 (hr) Agonisti glukagonskog receptora
HRP20240135T1 (hr) Fgf21 mutanti i njihove upotrebe
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
PE20190743A1 (es) Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib
AR039231A1 (es) Agentes de union ox40r novedosos
CL2012001686A1 (es) Analogo peptidico de oxintomodulina, en donde el aminoacido c-terminal es opcionalmente amidado; composicion farmaceutica que lo comprende y su uso en la preparacion de un medicamento para el tratamiento de diabetes no insulinodependiente u obesidad.
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
AR096162A1 (es) Péptidos terapéuticos
AR065349A1 (es) Coagonistas del receptor de glucagon/glp-1
DK1765860T3 (da) Ny-ESO-T.cellereceptor med höj affinitet
RU2011106744A (ru) Инсулин, стабилизированный галогеном
US20050124550A1 (en) Compounds that modulate the glucagon response and uses thereof
Žáková et al. Human insulin analogues modified at the B26 site reveal a hormone conformation that is undetected in the receptor complex
MX347229B (es) Antagonistas de péptido de la familia cgrp de calcitonina de hormonas de péptido y su uso.
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
Lu et al. Galanin receptor ligands
WO2011038900A3 (en) Peptide analogues of glucagon for diabetes therapy
Jiang et al. Bradykinin-related peptides (BRPs) from skin secretions of three genera of phyllomedusine leaf frogs and their comparative pharmacological effects on mammalian smooth muscles
Campos-Lira et al. Conorfamide-Sr3, a structurally novel specific inhibitor of the Shaker K+ channel
Kirby et al. Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogs
Cao et al. Molecular cloning, expression analysis and cellular localization of an LFRFamide gene in the cuttlefish Sepiella japonica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.